Recombinant Human Kallikrein 11 Protein, CF
R&D Systems, part of Bio-Techne | Catalog # 1595-SE
Key Product Details
Source
NS0
Accession #
Structure / Form
Pro form
Conjugate
Unconjugated
Applications
Enzyme Activity
Product Specifications
Source
Mouse myeloma cell line, NS0-derived human Kallikrein 11 protein
Glu19-Asn250, with an N-terminal signal peptide and a C-terminal 10-His tag
Glu19-Asn250, with an N-terminal signal peptide and a C-terminal 10-His tag
Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<1.0 EU per 1 μg of the protein by the LAL method.
N-terminal Sequence Analysis
Glu19
Predicted Molecular Mass
27 kDa
SDS-PAGE
40 kDa, reducing conditions
Activity
Measured by its ability to cleave a colorimetric peptide substrate, N-carbobenzyloxy-Lys-ThioBenzyl ester (Z-Lys-SBzl), in the presence of 5,5’Dithio-bis (2-nitrobenzoic acid) (DTNB). Edwards, K.M. et al. (1999) J. Biol. Chem. 274:30468.
The specific activity is >200 pmol/min/µg, as measured under the described conditions.
The specific activity is >200 pmol/min/µg, as measured under the described conditions.
Formulation, Preparation and Storage
1595-SE
| Formulation | Supplied as a 0.2 μm filtered solution in Tris, NaCl and CaCl2. |
| Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: Kallikrein 11
As a member of human tissue kallikrein family, Kallikrein 11, also known as hippostasin, trypsin-like serine protease and PRSS20, is encoded by the KLK11 gene (1). Two alternatively spliced forms exist, resulting in 250 (isoform 1) and 282 (isoform 2) amino acid sequences,respectively (2-5). Isoform 1 consists of a signal peptide (residues 1-18), a short pro peptide (residues 19-21) and the mature chain (residues 22-250). Isoform 2 is identical to isoform 1, except that a 32 amino acid segment is inserted in isoform 2 before residue 1 in isoform 1. Isoform 1 is predominantly expressed in brain whereas isoform 2 is preferentially expressed in prostate. KLK11 is a novel marker for ovarian and prostate cancer carcinomas (6-8). Recombinant human KLK11, after being activated by thermolysin, is active against a thioester substrate. This activity can be inhibited by AEBSF (Catalog # http://www.rndsystems.com/product_results.aspx?k=EI001">EI001), dichloroisocoumarin, and aprotinin. Recombinant human KLK11 produced by R&D Systems corresponds to isoform 1.
References
- Yousef, G.M. and E.P. Diamandis (2001) Endocrine Rev. 22:184.
- Yoshida, S. et al. (1998) Biochim. Biophys. Acta 1399:225.
- Yousef, G.M. et al. (2000) Genomics 63:88.
- Mitsui, S. et al. (2000) Biochem. Biophys. Res. Commun. 272:205.
- Gan, L. et al. (2000) Gene 257:119.
- Diamandis, E.P. et al. (2002) Cancer Res. 62:295.
- Nakamura, T. et al. (2003) Urology 61:1042.
- Borgono, C.A. et al. (2003) Int. J. Cancer 106:605.
Alternate Names
KLK11
Entrez Gene IDs
11012 (Human)
Gene Symbol
KLK11
UniProt
Additional Kallikrein 11 Products
Product Documents for Recombinant Human Kallikrein 11 Protein, CF
Product Specific Notices for Recombinant Human Kallikrein 11 Protein, CF
For research use only
Loading...
Loading...
Loading...